We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Anesthesia Drugs May Relieve Depression in Some

By HospiMedica International staff writers
Posted on 05 Apr 2010
A pilot study has found that repeated low doses of the anesthesia drug ketamine produced almost immediate relief from depression in patients with treatment-resistant depression (TRD) who did not respond to any other type of depression therapy.

Researchers at Mount Sinai School of Medicine (New York, NY, USA) and the University of Groningen (The Netherlands) studied the effects of repeated doses of ketamine in 10 medication-free symptomatic patients with TRD, who had previously shown a meaningful antidepressant response to a single dose of the drug. More...
The study protocol involved six intra-venous (IV) infusions of ketamine over 12 days; on day 1, the patients received a 40-min infusion of ketamine (0.5 mg/kg), in an inpatient setting with continuous vital-sign monitoring. Psychotomimetic and adverse events were recorded repeatedly, with the primary efficacy measure being change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) score. If the patients showed a 50% or higher reduction in MADRS scores on day 2, they received five additional infusions on an outpatient basis (days 3, 5, 8, 10, and 12). Follow-up visits were conducted twice weekly for four weeks, or until relapse.

The results showed that the response criterion was met by nine patients after the first infusion, and again after the sixth infusion, with the mean reduction in MADRS scores after the sixth infusion being 85%. Postketamine, eight of nine patients relapsed, on average, 19 days after the last infusion, with one patient remaining antidepressant-free with minimal depressive symptoms for over 3 months. The ketamine elicited minimal positive psychotic symptoms, with three patients experiencing significant but transient dissociative symptoms. The side effects during and after each ketamine infusion were generally mild. The study was published in the January 15, 2010, issue of Biological Psychiatry.

"These pilot findings suggest feasibility of repeated-dose intravenous ketamine for the acute treatment of treatment-resistant depression,” concluded lead author Marije aan het Rota, Ph.D., of the University of Groningen, and colleagues.

Ketamine is classified as an N-methyl d-aspartate (NMDA) receptor antagonist. At anesthetic level doses, ketamine has also been found to bind to opioid μ receptors and σ receptors. Like other drugs of this class, such phencyclidine (PCP, or "angel dust”), it induces a state referred to as "dissociative anesthesia,” often used as a recreational drug. Ketamine has a wide range of effects in humans, including analgesia, anesthesia, elevated blood pressure, and bronchodilation. Ketamine is primarily used for the induction and maintenance of general anesthesia, usually in combination with some sedative drug, and is a popular anesthetic in veterinary medicine.


Related Links:
Mount Sinai School of Medicine
University of Groningen


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.